Brief: Adverum Biotechnologies Completes IND Amendment And Prepares To Initiate The Phase 2 Luna Trial Of ADVM-022 In Wet AMD

Adverum Biotechnologies

06/07/2022 21:20

July 6 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES COMPLETES IND AMENDMENT AND
PREPARES TO
INITIATE THE PHASE 2 LUNA TRIAL OF ADVM-022 IN WET AMD
    * ADVERUM BIOTECHNOLOGIES INC- CASH RUNWAY EXTENDED INTO
2025
    * ADVERUM BIOTECHNOLOGIES INC- ANTICIPATE DOSING FIRST
PATIENT
WITH ADVM-022 IN Q3 OF 2022
    * ADVERUM BIOTECHNOLOGIES- LUNA TRIAL TO ENROLL UP TO 72
PATIENTS,
EXAMINE 2 DOSE LEVELS OF ADVM-022 ALONG WITH 4 NEW ENHANCED
PROPHYLACTIC STEROID REGIMENS
    * ADVERUM BIOTECHNOLOGIES INC- AS OF MARCH 31, 2022 ADVERUM
HAD
$271.1 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM
INVESTMENTS
    * ADVERUM BIOTECHNOLOGIES INC- HAVE TAKEN MEASURES TO
RESTRUCTURE
OUR OPERATIONS, INCLUDING REDUCTIONS IN BOTH HEADCOUNT AND
EXPENSES
    * ADVERUM BIOTECHNOLOGIES INC- RESTRUCTURING MEASURES ARE
INTENDED
TO ENABLE US TO FULLY SUPPORT OUR ADVM-022 DEVELOPMENT PLAN

Source text for Eikon:  ID:nGNXby6rK7 
Further company coverage:  ADVM.O 

 ((Reuters.Briefs@thomsonreuters.com;))